The Basics of Translation

Huda Y. Zoghbi is an investigator with the Howard Hughes Medical Institute
Science (Impact Factor: 31.48). 01/2013; 339(6117):250. DOI: 10.1126/science.1234799
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: The long-held but erroneous assumption of never-ending rapid growth in biomedical science has created an unsustainable hypercompetitive system that is discouraging even the most outstanding prospective students from entering our profession-and making it difficult for seasoned investigators to produce their best work. This is a recipe for long-term decline, and the problems cannot be solved with simplistic approaches. Instead, it is time to confront the dangers at hand and rethink some fundamental features of the US biomedical research ecosystem.
    Proceedings of the National Academy of Sciences 04/2014; 111(16). DOI:10.1073/pnas.1404402111 · 9.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Research advances build upon the validity and reproducibility of previously published data and findings. Yet irreproducibility in basic biologic and preclinical research is pervasive in both academic and commercial settings. Lack of reproducibility has led to invalidated research breakthroughs, retracted articles, and aborted clinical trials. Concerns and requirements for transparent, reproducible, and translatable research are accelerated by the rapid growth of "post-publication peer review," open access publishing, and data sharing that facilitate the identification of irreproducible data/studies; they are magnified by the explosion of high-throughput technologies, genomics, and other data-intensive disciplines. Collectively, these changes and challenges are decreasing the effectiveness of traditional research quality mechanisms and are contributing to unacceptable-and unsustainable-levels of irreproducibility. The global oncology and basic biologic research communities can no longer tolerate or afford widespread irreproducible research. This article discusses (i) how irreproducibility in preclinical research can ultimately be traced to an absence of a unifying life science standards framework, and (ii) makes an urgent case for the expanded development and use of consensus-based standards to both enhance reproducibility and drive innovations in cancer research. Cancer Res; 74(15); 1-6. ©2014 AACR.
    Cancer Research 07/2014; 74(15). DOI:10.1158/0008-5472.CAN-14-0925 · 9.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The number of academic drug discovery centres has grown considerably in recent years, providing new opportunities to couple the curiosity-driven research culture in academia with rigorous preclinical drug discovery practices used in industry. To fully realize the potential of these opportunities, it is important that academic researchers understand the risks inherent in preclinical drug discovery, and that translational research programmes are effectively organized and supported at an institutional level. In this article, we discuss strategies to mitigate risks in several key aspects of preclinical drug discovery at academic drug discovery centres, including organization, target selection, assay design, medicinal chemistry and preclinical pharmacology.
    dressNature Reviews Drug Discovery 04/2015; 14(4):279-94. DOI:10.1038/nrd4578 · 37.23 Impact Factor